# An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

> **NCT07680257** · EARLY_PHASE1 · RECRUITING · sponsor: **Celest Therapeutics (Shanghai) Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- CLDN18.2 Positive Solid Tumors

## Interventions

- **BIOLOGICAL:** SUV2208A cell injection
- **BIOLOGICAL:** SUV2208A
- **BIOLOGICAL:** SUV2208A

## Key facts

- **NCT ID:** NCT07680257
- **Lead sponsor:** Celest Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-27
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680257, "An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07680257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*